利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Methods to prevent tumor recurrence by blockade of tgf-beta
    2.
    发明申请
    Methods to prevent tumor recurrence by blockade of tgf-beta 审中-公开
    通过阻断tgf-β阻止肿瘤复发的方法

    公开(公告)号：US20060057145A1

    公开(公告)日：2006-03-16

    申请号：US10532374

    申请日：2003-10-24

    申请人： Jay Berzofsky ,  Masaki Terabe ,  So Matsui

    发明人： Jay Berzofsky ,  Masaki Terabe ,  So Matsui

    IPC分类号： A61K39/395 ,  A61K38/18

    CPC分类号： G01N33/74 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/76 ,  G01N33/5011 ,  G01N33/5041 ,  G01N33/5047 ,  G01N2333/495

    摘要： Methods are provided herein to prevent a tumor recurrence in a subject, involving administering to the subject an agent that blocks the TGF-β signaling pathway. In one embodiment, the agent inhibits the immunosuppressive effects of TGF-β. Also provided is a method of enhancing an immune respond in a subject to inhibit recurrence of a tumor by administering an agent which blocks the TGF-β signaling pathway. A method of enhancing the activity of an immune cell to inhibit recurrence of a tumor by contacting a TGF-β receptor-expressing cell with an agent which blocks the TGF-β signaling pathway is also provided, as are methods of screening for an agent that inhibits or measurably reduces the recurrence of a tumor.

    摘要翻译： 本文提供了防止受试者肿瘤复发的方法，包括向受试者施用阻断TGF-β信号传导途径的试剂。 在一个实施方案中，所述试剂抑制TGF-β的免疫抑制作用。 还提供了通过施用阻断TGF-β信号传导途径的试剂来增强受试者中免疫应答以抑制肿瘤复发的方法。 还提供了通过使表达TGF-β受体的细胞与阻断TGF-β信号传导途径的试剂接触来增强免疫细胞活性以抑制肿瘤复发的方法， 抑制或可测量地减少肿瘤的复发。

    Modified HCV peptide vaccines
    4.
    发明申请
    Modified HCV peptide vaccines 失效
    改良的HCV肽疫苗

    公开(公告)号：US20060275322A1

    公开(公告)日：2006-12-07

    申请号：US11429670

    申请日：2006-05-05

    申请人： Jay Berzofsky ,  Pablo Sarobe ,  Stephen Feinstone ,  Marian Major

    发明人： Jay Berzofsky ,  Pablo Sarobe ,  Stephen Feinstone ,  Marian Major

    IPC分类号： A61K39/12 ,  A61K39/395

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55538 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/24143 ,  C12N2770/24222 ,  C12N2770/24234

    摘要： Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO: 1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

    摘要翻译： 提供了具有氨基酸序列DLMGYIPAV（SEQ ID NO：1）的分离的肽，在氨基酸位置139包含L> A取代的分离的HCV核心多肽，具有SEQ ID NO：1的氨基酸序列的分离的HCV核心多肽 NO：2，以及HCV核心多肽的片段，其具有比整个HCV核心多肽更少的氨基酸并且包含SEQ ID NO：1的氨基酸序列。还提供了编码本发明的肽和多肽的核酸， 包含本发明核酸的载体和包含本发明的载体和核酸的细胞。 还提供了在受试者中产生免疫应答和/或治疗或预防受试者的HCV感染的方法，包括向受试者或受试者的细胞施用本发明的任何组合物。

    Malarial immunogen
    5.
    发明授权
    Malarial immunogen 失效
    疟疾免疫原

    公开(公告)号：US4886782A

    公开(公告)日：1989-12-12

    申请号：US19000

    申请日：1987-02-26

    申请人： Michael A. Good ,  Jay Berzofsky ,  Louis H. Miller

    发明人： Michael A. Good ,  Jay Berzofsky ,  Louis H. Miller

    IPC分类号： A61K39/00 ,  C07K14/445

    CPC分类号： C07K14/445 ,  A61K39/00 ,  Y10S514/895

    摘要： The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine. Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper T-cells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.

    摘要翻译： 已分析恶性疟原虫的环孢子（CS）蛋白，开发出新的抗孢子疟原虫疫苗。 该分子上T细胞识别位点的定位对疫苗设计至关重要。 通过使用设计用于预测T细胞位点和大面积H-2同系小鼠的算法，定位了一个主要的无应答T细胞。 当对应于该位点的合成肽与分子上的主要B细胞位点共价连接时，形成能够产生高效价抗体应答的免疫原。 该肽序列能够引发辅助性T细胞用于对完整的CS蛋白的二次应答。 该位点代表了重复区域以外的CS分子描述的第一个辅助T细胞位点，并且是该分子上主要的免疫显性T位点。 本文描述的方法在合理设计和构建更有效的疫苗中是有用的。

    Modified HCV peptide vaccines
    9.
    发明申请
    Modified HCV peptide vaccines 失效
    改良的HCV肽疫苗

    公开(公告)号：US20050129705A1

    公开(公告)日：2005-06-16

    申请号：US10770117

    申请日：2004-02-02

    申请人： Jay Berzofsky ,  Stephen Feinstone ,  Marian Major ,  Pablo Sarobe

    发明人： Jay Berzofsky ,  Stephen Feinstone ,  Marian Major ,  Pablo Sarobe

    IPC分类号： A61K39/00 ,  A61K39/29 ,  C07H21/04 ,  C07K14/02 ,  C07K14/18 ,  C12N15/40 ,  C12N15/86 ,  C12Q1/70

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55538 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/24143 ,  C12N2770/24222 ,  C12N2770/24234

    摘要： Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

    摘要翻译： 提供了具有氨基酸序列DLMGYIPAV（SEQ ID NO：1）的分离的肽，在氨基酸位置139包含L> A取代的分离的HCV核心多肽，具有SEQ ID NO：1的氨基酸序列的分离的HCV核心多肽 NO：2和HCV核心多肽的片段，其具有比整个HCV核心多肽更少的氨基酸并且包含SEQ ID NO：1的氨基酸序列。 还提供了编码本发明的肽和多肽的核酸，包含本发明的核酸的载体和包含本发明的载体和核酸的细胞。 还提供了在受试者中产生免疫应答和/或治疗或预防受试者的HCV感染的方法，包括向受试者或受试者的细胞施用本发明的任何组合物。